203 related articles for article (PubMed ID: 31395281)
1. Do estrogen, progesterone, P53 and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis?
Gülseren V; Kocaer M; Özdemir İA; Çakır İ; Sancı M; Güngördük K
Curr Probl Cancer; 2020 Feb; 44(1):100498. PubMed ID: 31395281
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Trovik J; Wik E; Werner HM; Krakstad C; Helland H; Vandenput I; Njolstad TS; Stefansson IM; Marcickiewicz J; Tingulstad S; Staff AC; ; Amant F; Akslen LA; Salvesen HB
Eur J Cancer; 2013 Nov; 49(16):3431-41. PubMed ID: 23932335
[TBL] [Abstract][Full Text] [Related]
3. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
Bonfitto VL; de Angelo Andrade LA
Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
[TBL] [Abstract][Full Text] [Related]
4. HE4 and CA125 as preoperative risk stratifiers for lymph node metastasis in endometrioid carcinoma of the endometrium: A retrospective study in a cohort with histological proof of lymph node status.
O'Toole SA; Huang Y; Norris L; Power Foley M; Shireen R; McDonald S; Kamran W; Ibrahim N; Ward M; Thompson C; Murphy C; D'Arcy T; Farah N; Heron E; O'Leary JJ; Abu Saadeh F; Gleeson N
Gynecol Oncol; 2021 Feb; 160(2):514-519. PubMed ID: 33213897
[TBL] [Abstract][Full Text] [Related]
5. Nomogram to Predict Risk of Lymph Node Metastases in Patients With Endometrioid Endometrial Cancer.
Pollom EL; Conklin CM; von Eyben R; Folkins AK; Kidd EA
Int J Gynecol Pathol; 2016 Sep; 35(5):395-401. PubMed ID: 26598977
[TBL] [Abstract][Full Text] [Related]
6. Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models.
Yang B; Shan B; Xue X; Wang H; Shan W; Ning C; Zhou Q; Chen X; Luo X
PLoS One; 2016; 11(5):e0155145. PubMed ID: 27163153
[TBL] [Abstract][Full Text] [Related]
7. Estrogen/Progesterone Receptor Expression and Cancer Antigen 125 Level as Preoperative Predictors to Estimate Lymph Node Metastasis in Endometrioid Endometrial Cancer.
Wang SC; Wu CH; Fu HC; Ou YC; Tsai CC; Chen YY; Wang YW; Hunag SW; Huang SY; Lan J; Lin H
Int J Gynecol Pathol; 2024 Jul; 43(4):316-325. PubMed ID: 37732995
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
9. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
10. To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma.
Yadav A; Sistla A; Swain M; Gowrishankar S; Padua M; Modi T; Himabindu R; Agarwal N; Kulkarni A; Bhandari T; Vudayaraju H; Chinnababu ; Reddy VA
Indian J Pathol Microbiol; 2024; 67(1):62-67. PubMed ID: 38358190
[TBL] [Abstract][Full Text] [Related]
11. A novel multivariable prediction model for lymphatic dissemination in endometrioid endometrial cancer: The lymph node Metastasis Risk Index.
Meydanli MM; Aslan K; Oz M; Muftuoglu KH; Yalcin I; Engin-Ustun Y
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():310-315. PubMed ID: 31377459
[TBL] [Abstract][Full Text] [Related]
12. Comparison of three different risk-stratification models for predicting lymph node involvement in endometrioid endometrial cancer clinically confined to the uterus.
Korkmaz V; Meydanli MM; Yalçın I; Sarı ME; Sahin H; Kocaman E; Haberal A; Dursun P; Güngör T; Ayhan A
J Gynecol Oncol; 2017 Nov; 28(6):e78. PubMed ID: 29027396
[TBL] [Abstract][Full Text] [Related]
13. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
Halperin R; Zehavi S; Habler L; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2001; 22(2):122-6. PubMed ID: 11446475
[TBL] [Abstract][Full Text] [Related]
15. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
[TBL] [Abstract][Full Text] [Related]
17. Risk Factors for Lymph Node Metastasis among Lymphovascular Space Invasion-Positive Women with Endometrioid Endometrial Cancer Clinically Confined to the Uterus.
Sarı ME; Meydanlı MM; Yalçın I; Şahin H; Çoban G; Çelik H; Kuşçu E; Gungor T; Ayhan A
Oncol Res Treat; 2018; 41(12):750-754. PubMed ID: 30419557
[TBL] [Abstract][Full Text] [Related]
18. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
[TBL] [Abstract][Full Text] [Related]
19. Selected immuno-histochemical markers in curettage specimens and their correlation with final pathologic findings in endometrial cancer patients.
Obeidat BR; Matalka II; Mohtaseb AA; Al-Kaisi NS
Pathol Oncol Res; 2013 Apr; 19(2):229-35. PubMed ID: 23055021
[TBL] [Abstract][Full Text] [Related]
20. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma.
Huvila J; Talve L; Carpén O; Edqvist PH; Pontén F; Grénman S; Auranen A
Gynecol Oncol; 2013 Sep; 130(3):463-9. PubMed ID: 23777659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]